Back to top

Analyst Blog

Incyte Corporation (INCY - Analyst Report) recently presented encouraging long-term data from a phase I/II study on Jakafi, for the treatment of bone marrow fibrosis, at the 2013 annual meeting of the American Society of Clinical Oncology (ASCO). Bone marrow fibrosis is a key feature of myelofibrosis (MF).

Results from the study showed that bone marrow fibrosis stabilized/improved after 24 and 48 months in most MF patients treated with Jakafi. The bone marrow fibrosis stabilization was however not seen in long-term treatment with hydroxyurea.

At the end of 48 months, bone marrow fibrosis stabilized in 56% of the patients and improved in 22% of the patients treated with Jakafi. The same was 44% and 0% respectively in patients treated with hydroxyurea.

Meanwhile, bone marrow fibrosis grade worsened in 37% and 25% of the patients treated with Jakafi at the end of 24 months and 48 months, respectively. Compared to this, bone marrow fibrosis grade worsened in 65% and 74% of patients treated with hydroxyurea at the end of 24 months and 48 months, respectively.

We note that Jakafi is already approved for the treatment of patients suffering from intermediate or high-risk myelofibrosis in the US. Jakafi is also being studied for the treatment of polycythemia vera, essential thrombocythemia, solid/other hematologic tumors and pancreatic cancer.

Moreover, Incyte’s pipeline also has INCB024360 (advanced malignancies), INCB28060 (solid tumors) and INCB39110 (myelofibrosis, rheumatoid arthritis, psoriasis) among others.

Incyte, a biopharmaceutical company, currently carries a Zacks Rank #4 (Sell). Other biopharma stocks such as Jazz Pharmaceuticals Public Limited Company (JAZZ - Analyst Report), Santarus, Inc. and Cubist Pharmaceuticals Inc. (CBST - Analyst Report) currently look better positioned. While, Jazz Pharma and Santarus carry a Zacks Rank #1 (Strong Buy), Cubist Pharma carries a Zacks Rank #2 (Buy).

Please login to Zacks.com or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research

Close

Are you a new Zacks Member or a visitor to Zacks.com?

Top Zacks Features

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
UNITED THER… UTHR 117.83 +28.51%
TRIQUINT SE… TQNT 20.67 +6.52%
VASCO DATA… VDSI 14.77 +4.68%
BANCO DO BR… BDORY 15.53 +3.95%
STRATTEC SE… STRT 80.24 +3.00%